ArticleBlood neoplasia2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) remains an incurable cancer and is characterized by a remitting-relapsing pattern. The choice of next line of therapy depends on patient-, disease-, and treatment-related factors. The Canadian Myeloma Research Group database (CMRG-DB) hosts information in ≥10 000 individuals with plasma cell disorders across major Canadian institutions. In this retrospective study, we evaluated therapy choices and outcomes of patients with MM undergoing third-line (3L) therapy using the CMRG-DB platform. All patients with relapsed MM in the CMRG-DB who started 3L therapy between January 2015 and December 2020 were potentially eligible. A total of 1125 patients were included. The most common 3L therapies included immunomodulatory agents (702 [62.4%]), proteasome inhibitors (PIs; 491 [43.6%]), and anti-CD38 monoclonal antibodies (CD38 mAb; 277 [24.6%]). Combinations of daratumumab plus lenalidomide with or without corticosteroid produced the best responses, with a median progression-free survival (mPFS) of 25.6 months (95% confidence interval [CI], 20-35.7). An anti-CD38 mAb plus pomalidomide with or without steroid and other PI-based regimens had a much shorter mPFS, between 6 and 9 months. Adverse prognosticators were high-risk fluorescence in situ hybridization, shorter time from myeloma diagnosis to 3L, triple-class exposure, previous PI exposure, and refractoriness to lenalidomide. The median overall survival was 29.7 months (95% CI, 26.4-32.8). Our findings highlight the role of anti-CD38 mAb combined with lenalidomide for improvement of 3L outcomes. The results of combinations selected for 3L therapy by Canadian hematologists provide information on resource use and benchmark outcomes, which, in turn, will be useful for multiple stakeholders in the rapidly evolving myeloma therapeutic landscape.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.